Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOT-1030 in Advanced Solid Tumors
NCT05060263Phase 1Completed
- Sponsor
- Huabo Biopharm
- Start
- Mar 2021
- Primary completion
- Nov 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HOT-1030 in solid tumor (7 cohorts), sponsored by Huabo Biopharm. Primary endpoint: Adverse Events at 1 year. Started Mar 2021; status: completed.
02
Drugs
HOT-1030
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05060263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060263.